Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, development, and commercialization of products for the treatment of genetic diseases. Co.'s product categories are: biologics, which include Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and Mepsevii® (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII; small molecules, which includes Dojolvi® for the treatment of long-chain fatty acid oxidation disorders; gene therapy, which includes DTX301 for the treatment of patients with ornithine transcarbamylase deficiency; and nucleic acid, which includes UX053 for the treatment of glycogen storage disease type III. The RARE stock yearly return is shown above.
The yearly return on the RARE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RARE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|